Daclizumab With Mycophenolate Mofetil and Sirolimus in Prevention of Acute Rejection in Cardiac Allograft Recipients
Heart Transplantation
Enrolment: 36 · Results not recorded
Loading the evidence…
Drug · Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor (INHIBITOR; direct interaction; prodrug of mycophenolic acid)
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
Heart Transplantation
Enrolment: 36 · Results not recorded
Prevention of Acute Rejection After Kidney Transplantation
Enrolment: 162 · Results not recorded
Evidence of Liver Transplantation
Enrolment: 195 · Results not recorded
Non Infectious Uveitis
Enrolment: 120 · Results not recorded
Acute Myeloid Leukemia · Non-Hodgkin Lymphoma · Myelodysplastic Syndrome
Enrolment: 135 · Results not recorded
Graft Failure · Sickle Cell Disease · Hemoglobinopathies
Enrolment: 62 · Results not recorded
End Stage Liver Disease
Enrolment: 25 · Results not recorded
1 studies reported at therapy level; 1 evidence entries itemised.
Model: Tacrolimus-induced nephrotoxicity and hepatotoxicity at 60 mg/kg body weight
Co-administration of mycophenolate mofetil restored creatinine and reduced the tacrolimus-induced rise in AST and ALT, decreased DNA damage in kidney and liver, and lowered malondialdehyde and protein carbonyl levels together with changes in catalase and superoxide dismutase activities.
Extraction: extract · Supplied extraction confidence: 0.7. Machine-extracted fields require source verification.